seems to be risk management guidelines. Anthracyclines are in high risk category. Recommended referral for medium and high risk category at time of treatment. For all treatments ongoing monitoring.
Zantrene is a special beast and not really contemplated, eg anti cancer + cardio protect within the guideline. They sugggest use of Dexrazoxane but not perfect.
If Zantrene does work as suggested I would suspect at a minimum SoC for medium / high risks and the ESC guideline help with such classification. For drop in Doxo replacement, only time will tell.
seems to be risk management guidelines. Anthracyclines are in...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.015(0.80%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.79 | $163.0K | 89.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34299 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 3635 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |